ExeVir

Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out

  • by

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round. ExeVir is a spin-out of Vlaams Instituut voor Biotechnologie (VIB), Belgium’s life sciences research institute and the company also… Read More »Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out